Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
- Professor in Women's Cancer (Consultant Gynaecological Oncologist
- Women's Cancer
- Inst for Women's Health
- Faculty of Pop Health Sciences
Martin Widschwendter is Professor in Women's Cancer, Head of the Department of Women’s Cancer at University College London (UCL) and a Consultant Gynaecological Oncology Surgeon at University College London Hospital (UCLH). He was awarded Fellow of the Royal College of Obstetrics and Gynaecology (FRCOG ad eundem) in 2016.
In 2001, having completed his training in Gynaecology and Obstetrics in Austria, Martin worked at the Norris Comprehensive Cancer Centre in Los Angeles (USA) and spent three years as the lead clinician and surgeon of a large breast cancer centre before embarking on a career at UCL/UCLH from 2005 where he undertook sub-speciality training in gynaecological oncology. Martin’s particular interest is in complex radical laparoscopic and open surgery. As part of the Institute for Women's Health at UCL, he established a large research group focusing on the role of early detection, risk prediction and prevention of breast and gynaecological cancers. Martin is an author on more than 160 papers, contributed to numerous text books, secured substantial grant income in the last ten years and is an Editor for the International Journal of Gynecological Cancer. He was also the lead of the ESGO European Network of Translational Research In Gynaecological Oncology (ENTRIGO) and has lectured widely on his research and clinical experience in the UK and abroad. Martin is lead and coordinator on the H2020 FORECEE programme (www.forecee.eu) and is an ERC Advanced Grant holder.
Prof Widschwendter’s research is focused on two main areas:
(1) Advances in laparoscopic surgery and minimal invasive strategies in gynaecological cancers.
(2) Early detection, risk prediction and prevention of gynaecological malignancies and breast cancer. Our key research questions are to understand how epigenetic signatures in various tissues are established and modulated, how they contribute to both health and disease, and what implications these epigenetic alterations have in particular on tumour biology. Our core hypothesis is that genes which are reversibly repressed in stem cells and expressed during differentiation are a prime target for aberrant promoter methylation and gene silencing in cancer, and that this process is triggered by age, environmental and developmental factors, and transgenerational inheritance. We address this question within large collaborative programs. Early detection is addressed within the EU FP7 funded program EpiFemCare (EPIgenetics for FEMale personalised cancer CARE; www.epifemcare.eu) which Prof Widschwendter is coordinating and risk prediction and prevention programs are covered within FORECEE (www.forecee.eu) and BRCA PROTECT (www.brcaprotect.org) and other programmes.
Within the ERC Advanced Grant Martin will develop entirely new pathways for early breast and ovarian cancer detection and prevention.
Involvement in undergraduate and postgraduate teaching. Had nine PhD & MD students in the past. Currently supervising two PhD students and one MD student.
Surgical training of subspeciality trainees in gynaecological oncology.
Module lead of MSc course on women specific cancers.
Organising numerous international life-operating courses.
Editor of the International Journal of Gynecological Cancer.
|01-JUL-2011||Head of Department||Department of Women's Cancer||, United Kingdom|
|01-JUL-2009||Professor of Women's Cancer||Department of Women's Cancer||UCL, United Kingdom|
|01-OCT-2007||Consultant Gynaecological Oncology Surgeon||Gynaecological Oncology||UCLH, United Kingdom|
|1992||MD||Doctor of Medicine – Medicine||Universitat Innsbruck|